PTN Stock Forecast 2022, 2023, 2024, 2025, 2030
Despite having made no formal news today, the PTN Stock price of Palatin Technologies Inc. (NYSEAMERICAN: PTN) rose 33.7 percent premarket. Today’s surge extended the PTN Stock rally for the third day as buyers acquired its shares.
One of the major key reasons for the current increase of PTN Stock Price might be H.C. Wainright analyst Joseph Pantginis’ recent analysis of the PTN Stock, in which he restated a buy recommendation and boosted his PTN Stock Forecast price from $2 to $5.
PTN Stock price is presently trading below $1, thus the average analyst PTN Stock Forecast price of 45 indicates significant upside.
Palatin Technologies Inc (PTN Stock) is also up 138.89 percent in the last week and has a Bullish outlook from PTN Stock Forecast 2022, 2022, 2023, 2024, 2025, 2030 experts.
PTN Stock Price Today
As of 10:00 a.m. on Monday, Nov. 29, Palatin Technologies Inc. (PTN Stock) was trading at $0.86, up $0.30, or 54.12 percent, from the last closing PTN Stock price of $0.56. Up to this point today, the PTN Stock price has ranged between $0.68 and $0.88. Today’s volume of PTN Stock is really high. So far, 21,502,882 shares have been exchanged, with an average volume of 6,441,044 shares.
Historical PTN Stock Price Data:
- PTN Stock Market Cap (Previous Close): 184.15 M
- PTN Stock Price in USD (Previous Close): 0.558
- Share Volume (Previous Close): 41.37 M
- PTN Stock Price in USD (Last): 0.796
- 52 Week Change of Palatin Technologies Inc Stock: 0.354
- 90-Day Moving Average of Palatin Technologies Inc Stock: 0.441
- Beta: 1.3751107508281
- 52 Week High Palatin Technologies Inc Stock Price: 1.3
- 52 Week Low Palatin Technologies Inc Stock Price: 0.33
- Palatin Technologies Inc Stock’s 50 Day Moving Average: 0.4143
- 200 Day Moving Average of PTN Stock Price: 0.4916
14-Days Historical Palatin Technologies Inc Stock Price Data:
|Date||Opening Palatin Technologies Inc Stock Price||Closing Palatin Technologies Inc Stock Price||Minimum Palatin Technologies Inc Stock Price||Maximum Palatin Technologies Inc Stock Price|
|2021-11-26||Open: 0.53||Close: 0.5576||Low: 0.4777||High: 0.5576|
|2021-11-24||Open: 0.461||Close: 0.5144||Low: 0.4419||High: 0.5586|
|2021-11-23||Open: 0.3579||Close: 0.3444||Low: 0.3443||High: 0.3579|
|2021-11-22||Open: 0.3678||Close: 0.354||Low: 0.3501||High: 0.3678|
|2021-11-19||Open: 0.375||Close: 0.3601||Low: 0.3601||High: 0.375|
|2021-11-18||Open: 0.38||Close: 0.3729||Low: 0.3722||High: 0.3888|
|2021-11-17||Open: 0.392||Close: 0.377||Low: 0.3755||High: 0.392|
|2021-11-16||Open: 0.397||Close: 0.385||Low: 0.3833||High: 0.397|
|2021-11-15||Open: 0.41||Close: 0.3977||Low: 0.39||High: 0.41|
|2021-11-12||Open: 0.4029||Close: 0.4007||Low: 0.3972||High: 0.4043|
|2021-11-11||Open: 0.404||Close: 0.4031||Low: 0.4||High: 0.4048|
|2021-11-10||Open: 0.41||Close: 0.4062||Low: 0.4051||High: 0.414|
|2021-11-09||Open: 0.4139||Close: 0.4105||Low: 0.4105||High: 0.4149|
|2021-11-08||Open: 0.4022||Close: 0.4134||Low: 0.4022||High: 0.4143|
What Does Palatin Technologies Do?
In the United States, Palatin Technologies, Inc., a biopharmaceutical business, produces targeted receptor-specific medicines for the treatment of different illnesses. Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual drive disorders, is the firm’s main product. It is also working on the oral formulation of PL8177, a specific MC1r agonist peptide that has passed a Phase I medical study for the treatment of inflammatory bowel disease.
Furthermore, the business is working on PL9643, a peptide melanocortin agonist active at various MCrs, such as MC1r and MC5r, for anti-inflammatory ocular applications like dry eye illness, as well as melanocortin peptides for diabetic retinopathy. Furthermore, it is working on PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular signs, as well as PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic illnesses, along with minimizing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is headquartered in Cranbury, New Jersey.
Is PTN Stock a Good Buy?
According to MarketBeat statistics, Palatin Technologies Inc has an average rating of Buy. The average rating score for Palatin Stock is 3.00, based on 3 buy ratings, no hold ratings, and no sell recommendations.
Who Owns Palatin Stock?
Below, you can find the top 10 owners of Palatin Technologies Inc Stock.
|Total value ($)||PTN Stocks
bought / sold
|The Vanguard Group, Inc.||4.07%||9,415,677||3,841,596||0||0.00%|
|BlackRock Fund Advisors||1.35%||3,131,704||1,277,735||+348||+0.01%|
|Geode Capital Management LLC||0.71%||1,651,856||673,957||0||0.00%|
|Acadian Asset Management LLC||0.40%||925,823||377,736||-878,716||-48.69%|
|Bridgeway Capital Management LLC||0.37%||864,100||352,553||-190,000||-18.02%|
|Winton Capital Management Ltd.||0.34%||780,370||318,391||-110,530||-12.41%|
|SSgA Funds Management, Inc.||0.30%||700,015||285,606||0||0.00%|
|Northern Trust Investments, Inc.(…||0.26%||607,991||248,060||+155,708||+34.43%|
|US Bancorp Asset Management, Inc.||0.07%||156,740||63,950||0||0.00%|
|D. E. Shaw & Co. LP||0.07%||157,665||64,327||+157,665||—|
PTN Stock News
Focusing on the Palatin Technologies Inc’s fundamentals, we can see that it met with the US Food and Drug Administration (FDA) to discuss the phase 3 research of its dry eye medication, which is slated to begin later this quarter.
Shareholders have also drawn to the firm because it is developing a therapy for COVID-19 based on excellent preclinical data from numerous inflammatory clinical studies and a lung injury type.
The PL8177 therapy was shown to preserve lung tissue, decrease inflammation, and diminish lung fibrosis.
Palatin Technologies Inc has also benefited from market preference for equities that might gain from the newest COVID-19 strain, which enhances the urgency of finding a solution for the sickness that has caused a global epidemic and massive lockdowns.
Nevertheless, it needs to be seen whether the present rise will endure long because it has taken on a parabolic structure, which is generally followed by a large reversal.
Traders should not pursue the Palatin Technologies Inc’s PTN Stock upward since greater possibilities may arise later when the inevitable drop arrives. Yet, nothing from the markets is permanent.
Palatin Technologies Inc Stock price increased 33.68 percent to $0.7454, up from the previous day’s close of $0.5576.
PTN Stock Forecast
- PTN Stock Forecast for the next days:
|Date||Palatin Technologies Inc Stock Price||Min Palatin Technologies Inc Stock Price||Max Palatin Technologies Inc Stock Price|
|2021-11-30||Price: 0.739||Min: 0.632||Max: 0.844|
|2021-12-01||Price: 0.777||Min: 0.672||Max: 0.879|
|2021-12-02||Price: 0.763||Min: 0.660||Max: 0.873|
|2021-12-03||Price: 0.771||Min: 0.666||Max: 0.872|
|2021-12-06||Price: 0.840||Min: 0.736||Max: 0.943|
|2021-12-07||Price: 0.769||Min: 0.668||Max: 0.871|
|2021-12-08||Price: 0.8070||Min: 0.7086||Max: 0.918|
|2021-12-09||Price: 0.794||Min: 0.679||Max: 0.90100|
|2021-12-10||Price: 0.8019||Min: 0.700||Max: 0.9072|
|2021-12-13||Price: 0.870||Min: 0.772||Max: 0.979|
- Targeted Palatin Stock Price in 14 days is 0.979 USD highest and 0.632 USD lowest.
- 52 Week High Palatin Technologies Inc Stock Price is 376.
- 52 Week Low Palatin Stock Price is 0.248.
- 45-Day Moving Average of Palatin Technologies Inc Stock is 0.332.
- 90-Day Moving Average of Palatin Technologies Inc Stock is 0.340.
- PTN Stock Price may fall from 0.796 USD to 0.283 USD. The change of Palatin Stock Price will be -64.443%.